

***Latest news concerning bladder cancer treatment  
Nordic cooperation and clinical trials***

**Programme:**

10.30 – 11.00: Coffee + registration

11.00 – 11.10: Welcome + introduction to NUCOG (Chairman Hans von der Maase, Professor and Head of department; Department of Oncology, Rigshospitalet, Copenhagen)

11.10 – 11.55: *“Present status and future development for metastatic bladder cancer treatment”*  
(Hans von der Maase; Professor and Head of department; Department of Oncology, Rigshospitalet, Copenhagen)

11.55 – 12.15: *“Vinflunine in ongoing and future trials in TCCU and other indications”*  
(Gustavo Villanova; M.D.; Medical Affairs Oncology, Pierre Fabre)

12.15 – 13.00: *“Recent insight into molecular alterations in bladder cancer and their use as biomarkers”*  
(Torben Ørntoft; professor and head of department; Department of clinical biochemistry; MOMA, Aarhus)

13.00 – 14.00: Lunch

14.00 – 14.30: *An Exploratory Phase I Study with Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract* ( Anders Ullén, consultant, Department of Oncology, Karolinska University Hospital, Stockholm)

14.30- 15.00.: *A randomized phase II study of Vinflunine versus Vinflunine/Pemetrexed as second-line treatment in patients with metastatic urothelial carcinoma prior treated with platinum* ( Helle Pappot; consultant, Department of Oncology, Rigshospitalet, Copenhagen )

15.00 – 15.15: How to join the NUCOG initiative? (NUCOG-members)

15.15 – 15.45: Coffee break

15.45 – 16.15: *A randomized multicenter study of carboplatin/gemcitabine versus vinflunine/gemcitabine as first line treatment in patients with metastatic urothelial carcinoma not eligible for cisplatin based chemotherapy* (Karin Holmsten, consultant, Department of Oncology, Karolinska University Hospital, Stockholm )

16.15 – 16.45: Input to further development of NUCOG protocols

16.45 – 17.30: How to monitor a Nordic trial? “*Successful monitoring of Nordic childhood and young adults leukemia*” ( Thomas Frandsen, consultant, pediatric clinic, Rigshospitalet ; Birgitte Vilsbøll Hansen, GCP-unit, Rigshospitalet)

17.30 – 17.45: Q & A

17.45 – 18.00: Next step

18.00: Buffet